Exogenous interferon-γ immunotherapy for invasive fungal infections in kidney transplant patients

American Journal of Transplantation

Volumn 10, Issue 8, 2010, Pages 1796-1803

  Armstrong James, D ^a   Teo, I A ^a   Shrivastava, S ^a   Petrou, M A ^a   Taube, D ^a   Dorling, A ^a,b   Shaunak, S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Interferon (IFN ) immunotherapy; invasive fungal infections; kidney transplantation

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; CASPOFUNGIN; CYCLOSPORIN A; DACLIZUMAB; FLUCONAZOLE; FLUCYTOSINE; IMMUNKIN; IMMUNOGLOBULIN; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; PREDNISOLONE; RECOMBINANT GAMMA INTERFERON; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COST CONTROL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GRAFT RECIPIENT; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MALE; PHAEOHYPHOMYCOSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES;

EID: 77954930278     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03094.x     Document Type: Article

References (49)

1. Singh N. Invasive aspergillosis in organ transplant recipients: New issues in epidemiologic characteristics, diagnosis, and management. Med Mycol 2005 43 (Suppl 1 S267 S270.
2. Segal BH. Aspergillosis. N Eng J Med 2009 360 : 1870 1884.
3. Kohno S. High mortality in invasive aspergillosis: What we need to know for determination of poor prognosis and next countermeasures. Clin Infect Dis 2008 47 : 1185 1187.
4. Singh N, Dromer F, Perfect JR et al. Cryptococcosis in solid organ transplant recipients: Current state of the science. Clin Infect Dis 2008 47 : 1321 1327.
5. Sun H-Y, Wagener MM, Singh N. Cryptococcosis in solid organ, hematopoietic stem cell, and tissue transplant recipients: Evidence based evolving trends. Clin Infect Dis 2009 48 : 1566 1576.
6. Ben-Ami R, Lewis RE, Raad II et al. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009 48 : 1033 1041.
7. Sun H-Y, Aguado JM, Bonatti H et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant 2009 9 : 2166 2171.
8. Singh N, Aguado JM, Bonatti H, Forrest G et al. Zygomycosis in solid organ transplant recipients: A prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009 200 : 1002 1011.
9. Almyroudis NG, Sutton DA, Linden P et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006 6 : 2365 2374.
10. Allison AC, Eugui EM. Mechanisms of action of mycophenaloate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005 80 : S181 S190.
11. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporine A and tacrolimus. Scand J Immunol 2003 57 : 93 98.
12. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562 2575.
13. Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation 2008 86 : 761 767.
14. Bhatti Z, Shaukat A, Almyroudis NG et al. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipient. Mycopathologia 2006 162 : 1 15.
15. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National nosocomial infections surveillance system. J Infect Dis 1993 167 : 1247 1251.
16. Girmenia C, Barosi G, Aversa F et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: Results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 2009 49 : 1226 1236.
17. Page AV, Liles WC. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients. Curr Opin Organ Trans 2008 13 : 575 580.
18. Hamill P, Brown K, Jenssen H et al. Novel anti-infectives: Is host defence the answer? Curr Opin Biotechnol 2008 19 : 628 636.
19. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010 50 : 291 322.
20. Leventakos, K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: How do we prevent and treat them? Clin Infect Dis 2010 50 : 405 415.
21. Cenci E, Perito S, Enssle KH et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immunity 1997 65 : 564 570.
22. Del Sero G, Mencacci A, Cenci E et al. Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect 1999 1 : 1169 1180.
23. Mencacci A, Cenci E, Bacci A et al. Cytokines in candidiasis and aspergillosis. Curr Pharm Biotechnol 2000 1 : 235 251.
24. Armstrong-James D, Turnbull S, Teo I et al. The early host response to murine invasive pulmonary aspergillosis is associated with impaired interferon-γ production, a TNF-α directed pro-inflammatory transcriptional program and increased expression of IL-5 and IL-17. J Infect Dis 2009 200 : 1341 1351.
25. Summers SA, Dorling A, Boyle JJ et al. Cure of disseminated cryptococcal infection in a renal allograft recipient after the addition of γ-interferon to antifungal therapy. Am J Transplant 2005 5 : 2067 2069.
26. Shaunak S, Teo IA, Dorling A. Rapidly curative interferon-γ immuno-therapy for disseminated fungal infections in renal transplant patients. Quarterly J Med 2009 102 : 642 643.
27. Einsiedel L, Gordon DL, Dyer JR. Paradoxical inflammatory reaction during treatment of Cryptocosccus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin Infect Dis 2004 39 : e78 e82.
28. Brouwer AE, Siddiqui AA, Kester MI et al. Immune dysfunction in HIV-seronegative, Cryptococcus gattii meningitis. J Infect 2007 54 : e165 e168.
29. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts - approved standard M27-A2.
30. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi - approved standard M38-A. CLSI.
31. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob Agents Chemother 2009 53 : 24 34.
32. Sun H-Y, Alexander BD, Lortholary O et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009 49 : 1721 1728.
33. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care (Engl) 2001 10 : 56 62.
34. Bozza S, Zelante T, Moretti S et al. Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol 2008 180 : 4022 4031.
35. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003 57 : 93 98.
36. Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections-all neutropenic patients are not the same. Clin Infect Dis 1994 18 : 793 798.
37. Cenci E, Mencacci A, Del Sero G et al. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Infect Dis 1997 176 : 217 226.
38. Kawakami K. Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans. Jpn J Infect Dis 2004 57 : 137 145.
39. D'Elios MM, Josien R, Manghetti M et al. Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney Int. 1997 51 : 1876 1884.
40. Krook H, Wennberg L, Hagberg A et al. Immunosuppressive drugs in islet xenotransplantation: A tool for gaining further insights in the mechanisms of the rejection process. Transplantation 2002 74 : 1084 1089.
41. Ferraris JR, Tambutti ML, Cardoni RL et al. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: Changes in the immune responses. Transplantation 2004 77 : 532 537.
42. Smith KG, Isbel NM, Catton MG et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998 13 : 160 164.
43. Frassanito MA, Dammacco R, Fusaro T et al. Combined cyclosporin-A/ prednisone therapy of patients with active uveitis suppresses IFN-γ production and the function of dendritic cells. Clin Exp Immunol 2003 133 : 233 239.
44. Murray HW. Current and future clinical applications of IFN-γ in host antimicrobial defense. Intensive Care Med 1996 22 : S456 S461.
45. Hallstrand TS, Ochs HD, Zhu Q et al. Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency. Eur Respir J 2004 24 : 367 370.
46. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with IFN-γ via aerosol. Lancet 1997 349 : 1513 1515.
47. Pappas PG, Bustamante B, Ticona E et al. Recombinant IFN-γ1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004 189 : 2185 2191.
48. Siddiqui AA, Brouwer AE, Wuthiekanun V et al. IFN- γ at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005 174 : 1746 1750.
49. Kamar N, Milioto O, Puissant-Lubrano B et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010 10 : 89 98.